Syncom Formulations (India) Ltd (SYNCOMF) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 831770,
    "name": "Syncom Formul.",
    "stock_name": "Syncom Formul.",
    "full_name": "Syncom Formulations (India) Ltd",
    "name_url": "stocks-analysis/syncom-formul",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "13.22",
    "chg": 0.28,
    "chgp": "2.16%",
    "dir": 1,
    "prev_price": "12.94",
    "mcapval": "1,242.68 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524470,
    "symbol": "SYNCOMF",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE312C01025",
    "curr_date": "Jul 29, 02:21 PM",
    "curr_time": "14:22 PM",
    "last_traded_at": "Jul 29, 02:21 PM IST",
    "bse_nse_vol": "5.76 lacs",
    "exc_status": "Active",
    "traded_date": "Jul 29, 2026",
    "traded_date_str": "2026 07 29",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/syncom-formul-831770-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Syncom Formulations (India) Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/syncom-formulations-india-ltd-is-rated-sell-4120184",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/SyncomFormulati_mojoScore_4120184.png",
        "date": "2026-07-25 10:10:28",
        "description": "Syncom Formulations (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 February 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 25 July 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trend, and technical outlook."
      },
      {
        "title": "Syncom Formulations Faces Bearish Momentum Amid Technical Downgrade",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/syncom-formulations-faces-bearish-momentum-amid-technical-downgrade-4117032",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/SyncomFormulati_technicaldot_4117032.png",
        "date": "2026-07-23 08:03:19",
        "description": "Syncom Formulations (India) Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The stock’s recent downgrade from a Hold to a Sell rating reflects growing concerns over its price momentum and technical health amid broader market pressures."
      },
      {
        "title": "Syncom Formulations (India) Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/syncom-formulations-india-ltd-is-rated-sell-4100643",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/SyncomFormulati_mojoScore_4100643.png",
        "date": "2026-07-14 10:11:27",
        "description": "Syncom Formulations (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 14 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Syncom Formulations (India) Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/syncom-formulations-india-ltd-is-rated-sell-4087349",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/SyncomFormulati_mojoScore_4087349.png",
        "date": "2026-07-03 10:11:16",
        "description": "Syncom Formulations (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Syncom Formulations (India) Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/syncom-formulations-india-ltd-is-rated-sell-4067070",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/SyncomFormulati_mojoScore_4067070.png",
        "date": "2026-06-22 10:12:49",
        "description": "Syncom Formulations (India) Ltd is rated Sell by MarketsMOJO. This rating was last updated on 12 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 22 June 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Syncom Formulations (India) Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/syncom-formulations-india-ltd-is-rated-sell-4046387",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/SyncomFormulati_mojoScore_4046387.png",
        "date": "2026-06-11 10:10:57",
        "description": "Syncom Formulations (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 February 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 11 June 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and technical outlook."
      },
      {
        "title": "Syncom Formulations (India) Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/syncom-formulations-india-ltd-is-rated-sell-4024226",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/SyncomFormulati_mojoScore_4024226.png",
        "date": "2026-05-31 10:10:42",
        "description": "Syncom Formulations (India) Ltd is rated Sell by MarketsMOJO. This rating was last updated on 12 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 31 May 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Syncom Formulations Valuation Shifts Signal Growing Price Pressure Amid Sector Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/syncom-formulations-valuation-shifts-signal-growing-price-pressure-amid-sector-dynamics-4012450",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/SyncomFormulati_valuationdot_4012450.png",
        "date": "2026-05-26 08:01:25",
        "description": "Syncom Formulations (India) Ltd has seen a notable shift in its valuation parameters, moving from fair to expensive territory, as reflected in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios. Despite a strong recent price rally, the company’s valuation now demands closer scrutiny against its historical averages and peer group benchmarks within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Are Syncom Formulations (India) Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-syncom-formulations-india-ltd-latest-results-good-or-bad-4008951",
        "imagepath": "",
        "date": "2026-05-23 19:22:53",
        "description": "Syncom Formulations (India) Ltd's latest financial results for Q4 FY26 present a complex picture of the company's performance. The company reported a net profit of ₹25.17 crores, reflecting a significant year-on-year increase of 42.28%, and a quarter-on-quarter growth of 33.10%. This profit growth is notable, yet it is essential to recognize that it is heavily influenced by non-operating income, which constituted a substantial portion of the profit before tax.\n\nIn terms of revenue, Syncom recorded ₹135.41 crores, which represents a year-on-year decline of 9.05%, continuing a trend of revenue volatility. However, on a quarter-on-quarter basis, revenue showed a recovery with a growth of 17.60%, following a previous decline in the prior quarter. This indicates some short-term operational recovery, but the longer-term revenue trajectory remains concerning, particularly given the company's five-year sales declin..."
      }
    ],
    "total": 281,
    "sid": "831770",
    "stock_news_url": "https://www.marketsmojo.com/news/syncom-formulations-india-831770"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "10-Jul-2026",
      "details": "Certificate for compliance of regulation 74(5) of SEBI (Depositories and Participants) Regulation 2018 for the quarter ended 30th June 2026",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "25-Jun-2026",
      "details": "Notice for Trading window Closure for the financials of the quarter ended 30.06.2026",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "23-May-2026",
      "details": "Submission of Press Clipping related to extract of Audited Financial Results for the year ended 31.03.2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Syncom Formulations (India) Ltd has declared <strong>3%</strong> dividend, ex-date: 09 Sep 22",
          "dt": "2022-09-09",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Syncom Formulations (India) Ltd has announced <strong>1:10</strong> stock split, ex-date: 19 Aug 13",
          "dt": "2013-08-19",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Syncom Formulations (India) Ltd has announced <strong>5:2</strong> bonus issue, ex-date: 19 Aug 13",
          "dt": "2013-08-19",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Syncom Formulations (India) Ltd has announced <strong>1:2</strong> rights issue, ex-date: 13 May 09",
          "dt": "2009-05-13",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Syncom Formulations (India) Ltd is Rated Sell

2026-07-25 10:10:28

Syncom Formulations (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 February 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 25 July 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trend, and technical outlook.

Read full news article

Syncom Formulations Faces Bearish Momentum Amid Technical Downgrade

2026-07-23 08:03:19

Syncom Formulations (India) Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The stock’s recent downgrade from a Hold to a Sell rating reflects growing concerns over its price momentum and technical health amid broader market pressures.

Read full news article

Syncom Formulations (India) Ltd is Rated Sell

2026-07-14 10:11:27

Syncom Formulations (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 14 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Syncom Formulations (India) Ltd is Rated Sell

2026-07-03 10:11:16

Syncom Formulations (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Syncom Formulations (India) Ltd is Rated Sell

2026-06-22 10:12:49

Syncom Formulations (India) Ltd is rated Sell by MarketsMOJO. This rating was last updated on 12 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 22 June 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Syncom Formulations (India) Ltd is Rated Sell

2026-06-11 10:10:57

Syncom Formulations (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 February 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 11 June 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and technical outlook.

Read full news article

Syncom Formulations (India) Ltd is Rated Sell

2026-05-31 10:10:42

Syncom Formulations (India) Ltd is rated Sell by MarketsMOJO. This rating was last updated on 12 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 31 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Syncom Formulations Valuation Shifts Signal Growing Price Pressure Amid Sector Dynamics

2026-05-26 08:01:25

Syncom Formulations (India) Ltd has seen a notable shift in its valuation parameters, moving from fair to expensive territory, as reflected in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios. Despite a strong recent price rally, the company’s valuation now demands closer scrutiny against its historical averages and peer group benchmarks within the Pharmaceuticals & Biotechnology sector.

Read full news article

Are Syncom Formulations (India) Ltd latest results good or bad?

2026-05-23 19:22:53

Syncom Formulations (India) Ltd's latest financial results for Q4 FY26 present a complex picture of the company's performance. The company reported a net profit of ₹25.17 crores, reflecting a significant year-on-year increase of 42.28%, and a quarter-on-quarter growth of 33.10%. This profit growth is notable, yet it is essential to recognize that it is heavily influenced by non-operating income, which constituted a substantial portion of the profit before tax. In terms of revenue, Syncom recorded ₹135.41 crores, which represents a year-on-year decline of 9.05%, continuing a trend of revenue volatility. However, on a quarter-on-quarter basis, revenue showed a recovery with a growth of 17.60%, following a previous decline in the prior quarter. This indicates some short-term operational recovery, but the longer-term revenue trajectory remains concerning, particularly given the company's five-year sales declin...

Read full news article

View All News